# Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Canonical URL: https://biopharmsignal.com/news/CORT/corcept-to-present-new-data-from-pivotal-phase-3-rosella-trial-of-lifyorlitm-relacorilant-in-patients-with-platinum-resistant-ovarian-cancer-at-asco-2026
Ticker: CORT
Company: Corcept
Source: Corcept
Published: 2026-04-21 17:09 EST
Original Source URL: https://ir.corcept.com
## Summary

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Apr. 21, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

## Article Body
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Apr. 21, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the
## Recent Company News
- 2026-05-29 20:33 EST — [Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure](https://biopharmsignal.com/news/CORT/corcept-presents-new-data-at-asco-2026-lifyorlitm-overall-survival-across-all-subgroups-of-patients-with-platinum-resistant-ovarian-cancer-including-those-with-recent-taxane-exposure) — Source: Corcept
- 2026-05-27 12:00 EST — [Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome](https://biopharmsignal.com/news/CORT/corcept-to-resubmit-its-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-cushing-s-syndrome) — Source: Corcept
- 2026-04-30 20:05 EST — [Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis](https://biopharmsignal.com/news/CORT/corcept-phase-2-study-of-dazucorilant-demonstrates-two-year-overall-survival-benefit-in-patients-with-amyotrophic-lateral-sclerosis) — Source: Corcept
- 2026-04-30 20:05 EST — [Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CORT/corcept-therapeutics-announces-first-quarter-financial-results-and-provides-corporate-update) — Source: Corcept
- 2026-04-23 20:05 EST — [Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call](https://biopharmsignal.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update-and-host-conference-call) — Source: Corcept
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)